The Daily Briefing 1.13.2021

Drug overdose deaths have reached record levels in the United States, with an overwhelming majority of fatalities linked to opioids. Yet that hasn’t stopped Carl Hart, a psychology professor at Columbia University, from writing in a new book that the “opioid crisis” should have square quotes around it and even more absurdly, that the predominant effects of hard drugs such as heroin, cocaine and meth are “positive.” A daily heroin user, Hart declares that most opioid overdoses are actually the result of opioids mixed with alcohol or other sedatives—as if that makes a difference to the victim or his or her family. He confuses questions about the decriminalization of drugs, which is appropriate, with addiction as a disease, arguing that everyone has the right to “the pursuit of pleasure.” As drugs continue to destroy lives and communities, this book trivializes the use of drugs and minimizes the impact of addiction—and is a disservice to all those struggling with substance abuse.

And finally, Forbes looks at the life of Sheldon Adelson, the casino mogul and backer of anti-marijuana legislation who died this week. Adelson had a son who died of a drug overdose, which supposedly motivated him to become one of the strongest supporters of anti-legalization measures. But Adelson eventually stopped funding such campaigns, leaving the movement without a major backer at a time when public opinion was shifting decisively in favor of legalization.

The Daily Briefing 1.12.2021

As states rush to legalize marijuana—New York is the latest do propose legal weed—with a focus on generating tax revenue and advancing social justice, a flurry of new studies highlights the risks and dangers of consuming cannabis, which are rarely discussed. One study in the journal EClinicalMedicine shows that smoking weed may expose you to the same type of toxic chemicals found in tobacco smoke. In the study, those who only smoked marijuana had higher blood and urine levels of these chemicals.

Meanwhile, another study finds that teens and young adults between the ages of 14 and 25 were more likely to increase their use of alcohol while abstaining from cannabis, pointing to the addictive qualities of both substances. While avoiding any recreational substance use would be best for youth, this data suggests that teens avoiding cannabis use may be simply substituting their cannabis use for drinking—rather than giving up the substance entirely.

And finally, new research published in the journal JAMA Network Open found that vaping cannabis at any frequency was linked with symptoms of bronchitis and wheezing in young adults around 19 years old. Participants who had vaped cannabis had a stronger link to such symptoms—including daily cough, congestion and phlegm—compared to those who had never vaped cannabis. In 2018 an outbreak of vaping-related respiratory illnesses known as EVALI led to the hospitalization or deaths of more than 2,800 people. Such studies add to the preponderance of evidence showing that consuming marijuana can endanger health—especially for young people—and should therefore be a major consideration when lawmakers consider legalization.



The Daily Briefing 1.8.2021

Drug overdose deaths among the homeless population in Los Angeles rose sharply last year, fueled by the powerful synthetic opioid fentanyl. Overall fatalities increased 26 percent, with overdose the leading cause. Among the most commonly used drugs was methamphetamine, but this was often mixed with other substances including fentanyl, which was found in 41 percent of those who died, more than double from the previous year.

Meanwhile, the National Highway Traffic Safety Administration reports that the rate of car crash fatalities grew 18 percent last year despite fewer people on the road due to COVID-19 lockdowns. In addition to speeding and forgoing seat belts, the report found that driving while impaired was also a factor. Data from five trauma centers revealed a higher prevalence of alcohol, marijuana and opioids in crash victims compared with previous years.

And finally, marijuana stocks are rallying now that the Democrats have won control of the Senate, boosting hopes that this will lead to more progressive cannabis legislation—including federal-level legalization. President-elect Biden has called for the decriminalization of drugs and letting states decide on marijuana legalization, but he has stopped short of endorsing nationwide legalization. Currently, 15 states have fully legalized pot while another 16 have decriminalized the drug for non-medical use.

The Daily Briefing 1.7.2021

New York Governor Andrew Cuomo unveiled his long-awaited marijuana legalization plan, saying it would help raise tax revenue and support individuals and communities harmed by cannabis prohibition. In a statement, Cuomo noted that the positive impacts of legalization far outweigh the unnamed negatives—and that cannabis reform would raise tax revenues and support communities harmed by cannabis prohibition. The proposal establishes a new Office of Cannabis Management to oversee and regulate the drug, and enforce best practices to promote “responsible use” among adults as well as regulate packaging, labeling and advertising. It’s not clear what those regulations will be or the measures that are envisioned to protect vulnerable populations or communities that want to opt out of marijuana commerce. Cuomo has failed twice to enact legalization, but this time around he has a veto-proof Democratic supermajority in the state legislature—as well as a $15 billion budget gap to fill, although the expected $300 million annual returns are many years off.

Meanwhile, Governor Ned Lamont of neighboring Connecticut says he too is on board to push for marijuana legalization this year. If that happens, along with legalization in New York, a large swathe of the Northeast would become a legal pot zone, as New Jersey approved the measure last year.

And finally, Oregon is reaping at least the financial rewards of cannabis legalization, as pot sales soared to a record $1 billion in 2020 amid pandemic panic buying. State tax revenue from pot sales will likely exceed $150 million, with the bulk of that going to substance abuse programs linked to the state’s decriminalization of hard drugs.

The Daily Briefing 1.6.2021

If there was still any doubt in anyone’s mind about marijuana legalization in New York State, Governor Andrew Cuomo plans to make it official next week by announcing a detailed plan for legal adult-use recreational weed.Cuomo has failed twice before to win passage of cannabis reform, but this year he has support from a veto-proof Democratic supermajority in the state legislature. Still, Cuomo will need buy-in from swing suburban districts, which in the past have voiced concerns about impaired driving and children consuming pot. The proposal likely calls for setting aside marijuana tax revenue to encourage minority participation in the industry as well as for public health. Cuomo has said he favors legalization to boost state tax revenues to help plug the state’s $15 billion budget gap—although even supporters acknowledge that such money would not be available for many years.

Meanwhile, New Jersey is grappling with how to implement its new marijuana legalization law—in particular, whether to arrest or simply fine underage users. Recognizing the drug’s harmful effects on young people, some say law enforcement should not be entirely powerless to confiscate weed in order to discourage kids from using it, and instead of incarceration suggest a civil penalty with a small fine or community service.

And finally, with more states legalizing pot and sales booming during the pandemic, Ad Week believes that 2021 will usher in the “golden age” of cannabis marketing. This will include sophisticated packaging and branding that mimics mainstream (but hip) consumer goods and steers clear of old-style weed jargon and psychedelic colors. To succeed in this competitive market, products must be Instagrammable and worthy of “bringing to a dinner party,” says one marketer.

The Daily Briefing 1.5.2021

Opioid use and overdose deaths are soaring during the COVID-19 pandemic, and the construction industry in the U.S. has been particularly hard hit. Construction workers are prone to serious physical injuries, and often get hooked on strong prescription painkillers as well as street drugs such as heroin. While precise number of overdose fatalities in the industry isn’t known, construction workers are roughly 6 times more likely than workers in other manufacturing industries to become addicted to opioids. In Massachusetts, the construction industry employs almost 145,000 people and an estimated 25 percent of all opioid overdose deaths between 2011 and 2014. Unions and industry associations are stepping up efforts to tackle the problem with education and prevention programs.

Meanwhile, a new report from Pew Trusts underscores the effectiveness of using FDA-approved drugs to treat substance use—but points out that such drugs are often unavailable. The drugs—including methadone and buprenorphine— help people manage withdrawal symptoms, reduce illicit opioid use, and stay in treatment, as part of a behavioral health program. Yet despite these proven benefits, many people are not able to access such treatment, as nearly 44 percent of substance use treatment facilities do not offer any medication to treat opioid use disorder. Ensuring comprehensive coverage of all services and awareness of how such medications work are all integral factors in curbing the opioid epidemic, the report concludes.

And finally, data from the Substance Abuse and Mental Health Services Administration show that marijuana was the second most common substance involved in substance-related Emergency Department visits, with 22 percent. Young people are especially at risk, with patients aged 18 to 25 accounting for 27 percent of marijuana-related visits, the second largest proportion of these visits.

The Daily Briefing 1.4.2021

Substance-abuse providers are curtailing treatment and 10 percent have even shut down during the pandemic due to virus outbreaks, contributing to a spike in drug overdoses and fatalities. The New York Times takes a closer look at the impact of reduced services, noting that the advent of tele-health practices have helped but that virtual treatment cannot fully replace the benefits of in-person interactions. Nearly half of treatment centers in the U.S. have reduced patient capacity and nearly a third saw a decrease in patient retention, while 44 percent are conducting half their programming remotely. The majority of closures have been in the Northeast, due to the outbreak’s early concentration in New York.

Meanwhile, pharmacists at Walmart say they raised red flags for years about the retail chain’s in-store pharmacies doling out prescription opioids that appeared to be illegal—and were ignored. They are speaking out as the Justice Department pursues legal action against Walmart, saying its 5,000 pharmacies routinely filled billions of highly-addictive pills without proper safeguards and therefore contributed to the decades-long opioid epidemic (Walmart denies the charges).

And finally, Mexico is poised to legalize marijuana, making it the third country to do so —after Canada and Uruguay—and potentially the world’s largest market for cannabis with 88 million adults. With both Canada and Mexico now having legal cannabis, this could put pressure on the U.S. to follow suit, and accelerate the legalization movement beyond the 15 states that have so far legalized recreational marijuana. Legalization in Mexico won’t, however, have an impact on the country’s notorious drug cartels, analysts say, as cannabis makes up only a small percentage of their activities.

The Daily Briefing 12.23.2020

Nationwide opioid lawsuits took a new turn as the Department of Justice added Walmart to the list of alleged offenders, claiming that the giant retailer helped to fuel the opioid epidemic by inadequately monitoring prescriptions of highly addictive painkillers at its 5,000 in-store pharmacies. The lawsuit says Walmart sought to boost profits by pressuring employees to fill prescriptions quickly, and without proper monitoring and compliance, thereby turning the pharmacies into a leading supplier of opioids and enabling widespread drug use nationwide. Walmart joins other large companies—including drug manufacturers, drug distributors and retail pharmacy chains—in thousands of lawsuits brought by cities, states and the federal government alleging that aggressive marketing of painkillers are responsible for the deaths of hundreds of thousands of Americans over the past two decades.

Meanwhile, doctors and addiction experts say they want the federal government to extend the easing of drug treatment rules that were enacted during COVID-19—including the loosening of telehealth regulations. They say the changes have saved thousands of lives by making it easier to access treatment remotely, and should therefore continue beyond the pandemic.

And finally, San Francisco is the latest city to report soaring drug overdose fatalities in 2020, with deaths this year so far exceeding the number of people who died from COVID-19. The city said a record 621 died from drug overdose, outpacing 173 deaths from the corona virus. The crisis deepened amid the stress and isolation of COVID lockdowns, and because the powerful synthetic opioid fentanyl flooded the city’s drug supply.

The Daily Briefing 12.21.2020

New York State will likely legalize marijuana next year, but how it will embrace cannabis reform is still up in the air. Lawmakers and Governor Andrew Cuomo have proposed differing approaches, with the main sticking points being how to divvy up expected marijuana tax revenues—although it is unclear how much the state would make on pot sales and when the windfall would arrive. Cuomo says he supports legalization to help shore up the state’s battered COVID-19 economy and a projected $15 billion budget shortfall in 2021. Yet state budget analysts forecast tax revenue of only $20 million in the first year of operation, and an estimated $300 million in years to come—a drop in the bucket compared to the state’s urgent budget needs. Medical marijuana is already legal in New York, but after neighboring New Jersey legalized adult-use cannabis Cuomo obviously wants to make sure his state doesn’t miss out on commercial expansion, even if it compromises public health and safety.

Meanwhile, the Drug Enforcement Agency has changed its rules on federally sanctioned marijuana growing to accelerate scientific research into the drug. After years of delay, the DEA has expanded the number of businesses that can grow marijuana for federally approved study by scientists and doctors, to assess the possible dangers and benefits of cannabis that could lead to the development of marijuana-derived medicines approved by the FDA.

And finally, police in North Carolina have busted a drug ring and arrested 21 former students at colleges and universities in he state, charging them with dealing thousands of pounds of marijuana, along with cocaine and other drugs on campuses and in fraternity houses. They funneled large amounts of those drugs into universities and the surrounding towns, sometimes operating right out of their fraternity houses.

The Daily Briefing 12.18.2020

Several members of the billionaire Sackler family have voiced regret about the decades-long opioid epidemic and the role of their firm, Purdue Pharma, in the addiction crisis—but refused to accept any personal responsibility. Speaking in a rare appearance before a congressional committee, two members of the Sackler family—who served as Purdue board members—claimed they didn’t know about the company’s efforts to aggressively market OxyContin and downplay the drug’s addictiveness, which contributed to the deaths of more than 450,000 Americans over the past two decades. While three generations of the Sackler family have overseen Purdue since the 1950s, the family will pay only $225 million in civil penalties as part of a $8.3 billion settlement with the Justice Department over its role in the epidemic, but they will not face any criminal liability.

Meanwhile, one month after New Jersey voters approved the legalization of recreational marijuana, the state legislature has approved a regulatory framework for the cannabis market. It includes an opt-out provision for cities and towns that don’t want retail pot shops in their area, but will allow delivery services.

And finally, the Federal Trade Commission has finally begun a crackdown on deceptive marketing by CBD companies. In its first such action, the FTC has mandated that firms stop making “scientifically unsupported” claims about their products’ ability to treat medical conditions including cancer. It is also telling patients that CBD—the non-psychoactive component of marijuana—is not a miracle cure, and warns them not to stop taking prescription medicine without consulting a doctor.

The Daily Briefing 12.17.2020

Supporters of marijuana legalization often argue that it would benefit small businesses and minority-owned enterprises and communities of color that were disproportionately harmed during the decades long war on drugs. But guess what? More and more states report that big companies and deep-pocketed interests control the emerging marijuana market. Now, a merger of two Canadian cannabis companies points to further consolidation of Big Pot and its power. The combined companies—Aphria and Tilray—would be the largest cannabis operation globally by revenue, and it would control 17 percent of Canada’s adult-use market. More deals are likely, analysts say, as legalization continues, consumers adopt the “cannabis lifestyle,” and larger consumer-products makers also eye the opportunity to sell pot-infused foods, beverages and skin-care products.

At the same time, Big Pot is optimistic about more liberal marijuana policies under a Biden presidency that would allow the industry to flourish—even if the changes stop short of federal-level legalization. Opinion polls show an overwhelming majority of Americans favor legalization, and the issue is slowly gaining bipartisan support, especially at the state level.

And finally, New York Governor Andrew Cuomo has made it abundantly clear that he too favors legalization, and is ready to push it through the state legislature next year—in part to help plug a $15 billion budget gap caused by the COVID-19 economic downturn. Cuomo has twice failed to win passage of legalization, as bills stalled over taxes and where to allocate revenue. Now he’s more optimistic about cannabis reform, given that neighboring New Jersey this year approved legalization, and considering the state’s dire financial situation—although it’s uncertain how much money pot tax revenues would eventually bring in.

The Daily Briefing 12.15.2020

When Oklahoma legalized medical marijuana in 2018, few realized at the time that the traditionally conservative state would embrace the cannabis industry and over time become the biggest medical marijuana market in the country on a per capita basis. As Politico reports, a combination of factors—including few limits on marijuana licenses and scant restrictions on who can obtain a medical marijuana card—has led to what many now call a free-market marijuana utopia. More than 360,000 Oklahomans—nearly 10 percent of the state’s population—have medical marijuana cards, and to meet demand the state has 9,000 licensed marijuana businesses and 6,000 grow operations. What is happening in Oklahoma is indeed unprecedented—especially in a state that was once staunchly opposed to drug use—and could be seen as a model for other red states considering cannabis reform. Despite misgivings about legalization, two other strands of American culture—a live-and-let-live attitude and a preference for laissez-faire capitalism—have helped fuel the pot boom.

And finally, the booming market for products with CBD might not be booming for long, at least when it comes to food and beverage products containing the non-psychoactive component of marijuana. According to industry publication Food Business News, sales of such products plunged 75 percent this year, compared to 2019, when growth was up 115 percent. Are consumers getting wise to the bogus marketing claims that CBD is a cure-all for everything from anxiety to Alzheimer’s and even cancer and the corona virus? The sales decline is attributed to COVID-19, which has slowed impulse purchases at coffee shops and cafes. What’s more, retailers are hesitant to carry food and beverage products with CBD since the FDA has ruled that it cannot be used legally in food, beverages and dietary supplements. CBD is only approved for use in one drug for epilepsy, and there’s little scientific evidence suggesting it is effective for treating other health problems.

The Daily Briefing 12.14.2020

As speculation grows that President-elect Biden will bring back the position of “drug czar” to his cabinet to lead an all-out effort to address the drug crisis, a long list of potential candidatesare floating their names for consideration. Among them is Patrick Kennedy, the former congressman and mental health care advocate, as well as others well known in the fields of addiction medicine and public health. The flurry of activity reflects a new sense of anticipation that Biden will follow through on plans for a $125 billion initiative over the next decade to combat the opioid epidemic, and shift federal policy from incarceration for drug offenses to treatment. The drug czar would direct the Office of National Drug Control Policy, overseeing the budgets of other federal agencies involved in mental health care and addiction treatment, and also coordinating national and international policing efforts. The position has received little attention during the Trump administration, although whoever holds it is nominally the country’s highest-ranking drug policy official.

And finally, Ohio could be the next state to consider a bill to decriminalize low-level possession of hard drugs and expand drug treatment, following the approval last month of a similar measure in Oregon. The bill before the Ohio House would reduce penalties for possessing smaller amounts of drugs, both to keep individuals out of prison and to get them into treatment instead. However, one issue raised by the Ohio bill, as well as by the Oregon measure, is that entering treatment is entirely voluntary, which means that substance users would have little incentive to give up a life of drugs.

The Daily Briefing 12.11.2020

Now that marijuana legalization has gained momentum across the country, supporters of decriminalizing or legalizing psychedelic substances are gearing up make these drugs more widely accessible. Voters in Oregon and Washington, D.C., approved such measures this year for psilocybin mushrooms, and now activists in California are urging the Oakland City Council to adopt a resolution calling on the state to do the same—and to allow such drugs to be used in “healing ceremonies.” In Oregon, the measure authorized hallucinogens to treat mental health conditions, a move that was criticized by the American Psychiatric Association, saying there’s not enough scientific research showing that such drugs are safe and effective in clinical applications—and moreover, that treatment options for serious mental health conditions should not be decided by popular vote.

Meanwhile, one of the major selling points of marijuana legalization was that it would help bring about minority entrepreneurship by promoting ownership of pot shops by people of color, who suffered most during the war on drugs. But once again, the reality is quite different: in Illinois, nearly a year after legalization of recreational marijuana, there’s not a single licensed cannabis business that counts a person of color as majority owner. Instead, those who received licenses were people with deep pockets, political connections and ties to the burgeoning cannabis industry, which reported $580 million in sales so far this year in Illinois.

And finally, Florida is expected to be the next big state to consider cannabis reform, with pro-pot groups pushing for a ballot measure at a time when legalization enjoys broad popular support. Florida’s medical marijuana industry is already valued at around $1 billion, but the Republican-controlled legislature has so far blocked efforts to approve adult-use recreational pot.

The Daily Briefing 12.10.2020

As pro-marijuana legalization forces chalk up more state victories, it’s time to consider how to regulate emerging cannabis markets to safeguard public health. A Framework for Marijuana Control, published by National Families in Action and Smart Approaches to Marijuana, is based on alcohol and tobacco best practices and includes comparisons to what legal marijuana states have already enacted. It offers guidelines on critical issues such as the impact on adolescents, fetus and newborns; effects on both general and mental health; and how to ensure communities have the ability to opt-out of retail distribution. It also suggests ways to curb marketing to underage consumers, by prohibiting all forms of advertising, promotion and sponsorship, including on the Internet.

Meanwhile, the House has passed a bill with bipartisan support to expand marijuana research, following its recent approval of another bill to decriminalize marijuana on the federal level. The new bill would amend the Controlled Substances Act to remove limitations on researching marijuana, which lawmakers on both sides of the aisle agree is necessary to study the health effects of the drug.

And finally, Chicago and surrounding Cook County is the latest metropolitan area to report soaring opioid overdose deaths during the COVID-19 pandemic. Officials say it will be the worst year yet for fatal overdoses with 1,500 deaths so far—surpassing last year’s record-breaking tally. Latinos and Blacks make up 63 percent of the deaths, although they represent less than half of Cook County’s population. Overdoses are spiking across the country due to the isolation and stress of corona virus restrictions, as well as lack of access to drug treatment services.

The Daily Briefing 12.9.2020

Consulting firm McKinsey was deeply involved with advising opioid maker Purdue Pharma on how to boost sales of its highly addictive painkiller OxyContin—and has now issued a rare apology for its role in helping the drugmaker fuel the deadly opioid epidemic. According to recently released documents, McKinsey urged Purdue to pay distributors rebates for drug overdoses linked to their pills, and discussed destroying documents related to the opioid crisis. McKinsey has never accepted responsibility for helping Purdue sell more opioids, even as evidence mounted of abuse and overdose deaths.

Meanwhile, a new poll shows that a majority of Americans support marijuana legalization—in line with the findings of the 2020 Rosenthal Cannabis Study. The poll was taken after the House approved a bill to decriminalize marijuana on the federal level—the first to be approved by any chamber of Congress—which is not, however, likely to pass the Republican-led Senate.

And finally, President-elect Biden’s pick for Health and Human Services Secretary—California attorney general Xavier Becerra—has a strong track record of supporting cannabis reform in his state, and protecting California’s legal program from federal interference. What this eventually means for legalization is not yet clear, but the HSS chief will play a key role in deciding the fate of cannabis reform on the federal level.

The Daily Briefing 12.8.2020

In the wake of House passage of the MORE Act, which decriminalizes marijuana by removing the drug from the federal register of controlled substances, critics are voicing concerns about the possible impact of legalization on transportation and workplace safety. While the MORE Act is likely doomed in the Senate, it has inspired pro-legalization forces to push for cannabis reform in the new Biden administration. But workplace safety experts say that any de-scheduling must be done with care to evaluate the level of impairment caused by the drug in order to protect workers and all who use our roadways. Unfortunately, no cannabis test currently exists that accurately determines impairment, nor do we know the side effects of long-term health implications. Data should always drive policy decisions, and that’s why we need more rigorous research into the impact of marijuana.

Meanwhile, the Seattle Times reports that there are no Black-owned marijuana dispensaries in the city—despite the claims of legalization advocates that cannabis reform would benefit communities of color that suffered disproportionately from incarceration during the war on drugs. In reality, Black businesspeople have been left out of the state’s “green gold rush.”

And finally, an opinion piece in the New York Times says the Sackler family, founder of Purdue Pharma, may walk away from the company’s pending settlement with the Justice Department without public scrutiny or accountability. The company’s bankruptcy and a “poison pill” legal loophole could mean they would be released from liability, and it would become practically impossible to uncover the full truth about the billionaire Sackler family’s role in the opioid crisis.

The Daily Briefing 12.7.2020

The House passed landmark legislation decriminalizing marijuana on the federal level and expunging cannabis-related criminal convictions. Although the Democratic-proposed measure picked up five Republican votes —and six Democratic defections —it is likely doomed in the GOP-led Senate. Still, pro-legalization forces have hailed House approval as a major victory, as it’s the first of its kind to clear any chamber of Congress, and allows states to determine legality by removing cannabis from the federal register of controlled substances. Democratic lawmakers said the bill was essential to redress the disparities in drug-related incarceration that disproportionately impact communities of color; Republicans argued that legalization would harm children and endanger pubic safety, and said that now is not the time to focus on marijuana legalization.

Meanwhile, 2020 has become the worst year ever for drug overdose deaths in the nation’s capital, which recorded 282 fatalities as of August—surpassing the total for all of 2019. Officials blame the increase on the presence of the powerful synthetic opioid fentanyl, and the isolation and despair caused by the COVID-19 pandemic. But many blame the city government for not implementing a strategy to expand treatment and prevention programs.

And finally, a new study finds that nonfatal drug overdoses are on the rise among Americans younger than 15. Researchers say that overdoses between 2016 and 2019 rose 2 percent for all drugs—opioids, heroin and stimulants—in those ages 0-10, and 2.3 percent for those ages 11-14. While the data is troubling, the study says such events are still rare.

The Daily Briefing 12.4.2020

In response to the COVID-19 pandemic, federal officials eased access to drug treatment by allowing telehealth and telemedicine practices that were previously banned, and allowing Medicare and Medicaid to pay for such services. As a result, treatment providers could retain and attract new patients, at a time when social distancing and other restrictions curbed access. Now, with the advent of a corona virus vaccine, providers are pushing for these changes to be made permanent as part of a wider effort to expand treatment opportunities. For too long, the providers say, addiction treatment has been difficult to find, with only 1 in 10 individuals with a drug use disorder receiving specialty treatment. As the Rosenthal Center has found, telehealth is not a panacea for all patients, but it is a promising new tool in the drug treatment arsenal.

Meanwhile, critics of the $8.3 billion legal settlement between Purdue Pharma and the Justice Department say they want criminal charges brought against the firm’s founding Sackler family, for their role in fueling the opioid epidemic. The settlement didn’t include criminal charges against the Sacklers, nor did they admit wrongdoing, and they were required to pay only $225 million to settle civil claims—a small fraction of their wealth generated from sales of Purdue’s highly addictive opioid OxyContin.

And finally, the Democratic-controlled House is expected to pass a bill removing marijuana from the federal list of controlled substances, the first time either chamber of Congress has voted on the matter. While the bill is likely to be killed in the GOP-led Senate, it marks a watershed in public and political acceptance of cannabis reform, and comes a month after four additional states approved legalization of adult-use marijuana. The bill also calls for expunging marijuana criminal records and letting states set up rules and regulations to govern the cannabis market. As legalization moves ahead, it is critical for the states to focus on ensuring public health and safety—and protecting vulnerable populations and communities.